INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

INmune Bio Inc. has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited to establish a global commercialization framework for its allogeneic stromal cell therapy, Ebstrocel™, aimed at treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). The agreement will initially facilitate named-patient access in select European and MENA markets, with Uniphar providing services such as regulatory assessments and market access support. This partnership is designed to create a capital-efficient infrastructure for INmune Bio as it seeks regulatory approvals and reimbursement in various countries, with potential for broader commercial distribution in the future.